United States Ex Rel. Greenfield v. Medco Health Solutions, Inc.

880 F.3d 89
CourtCourt of Appeals for the Third Circuit
DecidedJanuary 19, 2018
Docket17-1152
StatusPublished
Cited by99 cases

This text of 880 F.3d 89 (United States Ex Rel. Greenfield v. Medco Health Solutions, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States Ex Rel. Greenfield v. Medco Health Solutions, Inc., 880 F.3d 89 (3d Cir. 2018).

Opinion

OPINION OF THE COURT

AMBRO, Circuit Judge

Accredo Health Group, Inc., a specialty pharmacy that provides home care for patients with' hemophilia (a rare condition that prevents blood from clotting properly), made donations to charities, two of which allegedly recommended Accredo as an approved provider for hemophilia patients. This raises whether the donations came with something expected in return for the recommendations, which might trigger violations of the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), and, if so, whether Accredo’s healthcare reimbursement claims for persons who may have received the charities’ recommendations ran afoul of the False Claims Act, 31 U.S.C. § 3729 (a)(l)(A)-(B). No federal agency, however, made a claim against Accredo. In stepped Steve Greenfield, a private citizen and a former area vice president of Accredo, who sued it and affiliates Medco Health Solutions, Inc., and Hemophilia Health Services, Inc. (for simplicity, all are referred to as “Accredo”) for - alleged violations of the two federal statutes. 1 If Greenfield prevailed, he would get at least 25% of any civil penalty or damages award.

The District Court, at the end of discovery, entered summary judgment against Greenfield and for Accredo, and the Government here has chosen not to intervene. It found that Greenfield failed to provide evidence of even a single federal claim for reimbursement, by Accredo that was linked to the alleged kickback scheme: As he disagrees, Greenfield appeals to us.

I. BACKGROUND

Accredo delivers clotting medication (medically called “clotting factor”) to patients at their homes and provides nursing assistance that is .tailored to hemophilia patients’ needs. Along .with its pharmaceutical services, Accredo makes donations to various charities, including two that are pertinent to. this appeal: Hemophilia Services, Inc. (“HSI”), and Hemophilia Association of New Jersey. (“HANJ,” and collectively with HSI, “HSI/HANJ”). From 2007 to 2012, Accredo’s donations to HSI/HANJ ranged from approximately $200,000 to $550,000 on an annual basis.

Accredo contributed funds to HSI, which in turn provided grant's to HANJ. HSI’s grants served two purposes—an insurance program for patients who are not eligible for Medicare or Medicaid, and support for outpatient hemophilia treatment centers. Accredo believed its donations went to HANJ’s insurance program, but was aware that HANJ also funded treatment centers.

. HANJ purportedly recognized Accre-do’s contributions by identifying it as an HSI-approved provider or HSI-approved vendor on its website. It stated HSI-approved vendors “maintain the highest *92 quality of care while providing [a] continuity of services and constantly supporting the community in numerous ways.” It also directed users to “[r]emember to work with our HSI [approved] providers” and included hyperlinks to the approved providers’ websites. HANJ also provided treatment centers with lists identifying specialty pharmacies that were designated as HSI-approved providers. Accredo was noted in one list as one of four HSI-approved vendors that “continually contribute to this community.”

Although Accredo donated approximately $363,000 to HSI/HANJ in 2010, it informed both charities that it planned to reduce its annual donation to $175,000 in the following year. In response, HSI sent a letter to its members informing them of Accredo’s reduced pledge and encouraging them to request that Accredo restore funding. HSI’s letter focused on the possible shortfalls to HANJ’s private insurance program; in HSI’s view, Accredo’s funding cuts would “placet] the Insurance Program in jeopardy of being ‘phased out’ and ceasing to exist in the foreseeable future.” HSI also forwarded a copy of the letter to treatment centers, stating that “[t]he attached [letter] is self explanatory. [Hemophilia Health Services]/Accredo has behaved despicably, while enjoying the fruits of HANJ’s labor.”

As a result of HSI’s letter, Accredo received approximately 75 letters from HSI members requesting an increase in funding. It then asked Greenfield (as noted, an area vice president for Accredo) to analyze the potential return on investment if it were to increase its annual donation from $175,000 to $350,000. It also requested him to project the “likely business deterioration to [its New Jersey] market share” if it opted not to increase funding. Greenfield’s analysis indicated that, absent a funding increase to $350,000, “all new and existing business [could be] at risk,” and Accredo could expect to “lose 100% of the margin” associated with patients who switched out of Accredo’s services. Based on this analysis, Accredo restored its annual donation to $350,000 in 2012.

Greenfield thereafter filed a qui tom suit against Accredo, alleging it violated the False Claims Act by falsely certifying it complied with the Anti-Kickback Statute. 2 Although the statutory scheme gave the Government the option to intervene in the suit, it declined to do so.'See 31 U.S.C. § 3730 (b)(2).

The case proceeded to summary judgment, where the parties’ cross-motions presented differing theories on whether Greenfield had established a False Claims Act violation. He argued Accredo violated the Act by paying kickbacks to HSI/HANJ in the form of charitable contributions to induce recommendations and referrals of Accredo by HSI/HANJ to its members. In Greenfield’s view, Accredo’s alleged kickback scheme amounted to a False Claims Act violation because at least some referrals or recommendations were directed to Medicare beneficiaries and because Accre-do falsely certified compliance with the Anti-Kickback Statute while submitting Medicare claims for payment. 3 Accredo ar *93 gued Greenfield could not prove a violation of the False Claims Act, as there was no evidence any federally insured patient purchased its prescriptions because of its contributions to HSI/HANJ.

The District Court denied Greenfield’s motion for summary judgment while granting that of Accredo. In the Court’s view, his claim required him to (1) “establish that defendants violated the [Anti-Kickback Statute] through [their] alleged quid pro quo arrangetnent with HANJ/ HSI” and (2) “show that, as a result of defendants’ [Anti-Kickback Statute] violation, defendants received payment from the federal government” in violation of the False Claims Act. United States ex rel. Greenfield v. Medco Health Sys., Inc., 223 F.Supp.3d 222 , 227 (D.N.J. 2016).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
880 F.3d 89, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-greenfield-v-medco-health-solutions-inc-ca3-2018.